Risk factors for acquisition of drug resistance during multidrug-resistant tuberculosis treatment, Arkhangelsk Oblast, Russia, 2005–2010

Emerging Infectious Diseases

Volumn 21, Issue 6, 2015, Pages 1002-1011

  Smith, Sarah E ^a   Ershova, Julia ^a   Vlasova, Natalia ^b   Nikishova, Elena ^b   Tarasova, Irina ^b   Eliseev, Platon ^b   Maryandyshev, Andrey O ^b,c   Shemyakin, Igor G ^d   Kurbatova, Ekaterina ^a   Peter Cegielski, J ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Arkhangelsk Regional Anti tuberculosis Dispensary   (Russian Federation)

^c NORTHERN STATE MEDICAL UNIVERSITY   (Russian Federation)

^d STATE RESEARCH CENTER FOR APPLIED MICROBIOLOGY AND BIOTECHNOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; DEATH; DNA SEQUENCE; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; RUSSIAN FEDERATION; TREATMENT FAILURE; TREATMENT OUTCOME; COHORT ANALYSIS; DRUG EFFECTS; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

ADULT; ANTITUBERCULAR AGENTS; COHORT STUDIES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RISK FACTORS; RUSSIA; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84929409685     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2106.141907     Document Type: Article

References (39)

1. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Geneva: The Organization; 2011. p. 6, 16-24.
2. Kennedy N, Fox R, Kisyombe GM, Saruni AOS, Uiso LO, Ramsay ARC, et al. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am Rev Respir Dis. 1993;148:1547-51. http://dx.doi.org/10.1164/ajrccm/148.6_Pt_1.1547
3. Heifets L, Lindholm-Levy P. Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis. Antimicrob Agents Chemother. 1989;33:1298-301. http://dx.doi.org/10.1128/AAC.33.8.1298
4. Peloquin CA, Berning S, Huitt G, Childs J, Singleton M, James G. Once-daily and twice-daily dosing of p-aminosalicylic acid granules. Am J Respir Crit Care Med. 1999;159:932-4. http://dx.doi.org/10.1164/ajrccm.159.3.9807131
5. Steenken W, Wolinsky E. Cycloserine: antituberculous activity in vitro and in the experimental animal. Am Rev Tuberc. 1956; 73:539-46.
6. Steenken W Jr, Montalbine V. The antituberculous activity of thioamide in vitro and in the experimental animal (mouse and guinea pig). Am Rev Respir Dis. 1960;81:761-3.
7. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med. 1993;329:784-91. http://dx.doi.org/10.1056/NEJM199309093291108
8. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med. 1993;328:527-32. http://dx.doi.org/10.1056/NEJM199302253280802
9. Cox HS, Niemann S, Ismailov G, Doshetov D, Orozco JD, Blok L, et al. Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance. Clin Infect Dis. 2007;44:1421-7. http://dx.doi.org/10.1086/517536
10. Wright A, Zignol M, Deun AV, Falzon D, Gerdes SR, Feldman K, et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet. 2009;373:1861-73.
11. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep. 2006;55:301-5.
12. Toungoussova OS, Mariandyshev AO, Bjune G, Caugant DA, Sandven P. Resistance of multidrug-resistant strains of Mycobacterium tuberculosis from the Archangel oblast, Russia, to second-line anti-tuberculosis drugs. Eur J Clin Microbiol Infect Dis. 2005;24:202-6. http://dx.doi.org/10.1007/s10096-005-1284-z
13. Eliseev PI, Maryandyshev AO, Nikishova EI, Tarasova IV, Gorina GP, Chryssanthou E, et al. Epidemiological analyses of tuberculosis in Archangelsk, Russia and implementation of a rapid assay for detection of resistance in this high burden setting. Int J Mycobacteriol. 2013;2:103-8. http://dx.doi.org/10.1016/j.ijmyco.2013.04.002
14. Zignol M, Dara M, Dean AS, Falzon D, Dadu A, Kremer K, et al. Drug-resistant tuberculosis in the WHO European Region: an analysis of surveillance data. Drug Resist Updat. 2013;16:108-15. http://dx.doi.org/10.1016/j.drup.2014.02.003
15. Laing RO, McGoldrick KM. Tuberculosis drug issues: prices, fixed-dose combination products and second-line drugs. Int J Tuberc Lung Dis. 2000;4:S194-207.
16. Gupta R, Cegielski JP, Espinal MA, Henkens M, Kim JY, Lambregts-Van Weezenbeek CS, et al. Increasing transparency in partnerships for health-introducing the Green Light Committee. Trop Med Int Health. 2002;7:970-6. http://dx.doi.org/10.1046/j.1365-3156.2002.00960.x
17. World Health Organization. Guidelines for establishing DOTS-Plus pilot projects for the management of multidrug-resistant tuberculosis. Geneva: The Organization; 2000. p. 9-31.
18. Gammino VM, Taylor AB, Rich ML, Bayona J, Becerra MC, Bonilla C, et al. Bacteriologic monitoring of multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projects. Int J Tuberc Lung Dis. 2011;15:1315-22. http://dx.doi.org/10.5588/ijtld.10.0221
19. Centers for Disease Control and Prevention. Public health mycobacteriology: a guide for the level III laboratory. Atlanta: The Centers; 1985. p. 159-85.
20. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. Geneva: The Organization; 2003. p. 17-84.
21. Cegielski JP, Dalton T, Yagui M, Wattanaamornkiet W, Volchenkov GV, Via LE, et al. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis. 2014;59:1049-63.
22. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep. 2006;55:301-5.
23. Shah NS, Wright A, Bai G-H, Barrera L, Boulahbal F, Martín Casabona N, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis. 2007;13:380-7. http://dx.doi.org/10.3201/eid1303.061400
24. Maus CE, Plikaytis BB, Shinnick TM. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2005;49:3192-7. http://dx.doi.org/10.1128/AAC.49.8.3192-3197.2005
25. Arkhangelsk Oblast Tuberculosis Control Program. Application for a DOTS PLUS pilot project. Green Light Committee. Arkhangelsk (Russia): The Program: 2002.
26. Sullivan EA, Palumbo L, Ebrahimzadeh A, Frieden TR, Sullivan EA, Frieden TR, et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet. 1995;345:1148-50. http://dx.doi.org/10.1016/S0140-6736(95)90980-X
27. Ershova JV, Kurbatova EV, Moonan PK, Cegielski JP. Acquired resistance to second-line drugs among persons with tuberculosis in the United States. Clin Infect Dis. 2012;55:1600-7. http://dx.doi.org/10.1093/cid/cis748
28. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2009; 13:1320-30.
29. Leimane V, Riekstina T, Holtz E, Zarovska V, Skripconoka L, Thorpe K, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet. 2005;365:318-26. http://dx.doi.org/10.1016/S0140-6736(05)17786-1
30. Yew WW, Chan CK, Chau CH, Tam CM, Leung CC, Wong PC, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest. 2000;117:744-51. http://dx.doi.org/10.1378/chest.117.3.744
31. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9:e1001300. http://dx.doi.org/10.1371/journal.pmed.1001300
32. Fillion A, Aubry A, Brossier F, Chauffour A, Jarlier V, Veziris N. Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis. Antimicrob Agents Chemother. 2013;57:4496-500. http://dx.doi.org/10.1128/AAC.00506-13
33. Yew WW, Chan CK, Leung CC, Chau CH, Tam CM, Wong PC, et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest. 2003;124:1476-81. http://dx.doi.org/10.1378/chest.124.4.1476
34. Cegielski JP, McMurray DN. The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals. Int J Tuberc Lung Dis. 2004;8:286-98.
35. Weis SE, Slocum PC, Blais FX, King B, Nunn M, Matney GB, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 1994;330:1179-84. http://dx.doi.org/10.1056/NEJM199404283301702
36. Han LL, Sloutsky A, Canales R, Naroditskaya V, Shin SS, Seung KJ, et al. Acquisition of drug resistance in multidrug-resistant Mycobacterium tuberculosis during directly observed empiric retreatment with standardized regimens. Int J Tuberc Lung Dis. 2005;9:818-21.
37. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9:153-61. http://dx.doi.org/10.1016/S1473-3099(09)70041-6
38. World Health Organization. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec. 2006;81:430-2.
39. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J. 2005;25:564-9. http://dx.doi.org/10.1183/09031936.05.00111304